Sam Brusco, Associate Editor07.14.23
Relievant Medsystems, a company aiming to transform vertebrogenic low back pain diagnosis and treatment, has released its next generation of Intracept access instruments. Relievant announced the next-gen instruments at the Fifth Annual American Society of Pain and Neuroscience (ASPN) Conference this week.
According to the company, the new instruments can provide more predictable and precise basivertebral nerve (BVN) targeting during the company’s Intracept procedure.
“We are committed to continued innovation in support of our physicians as we expand patient treatment with the Intracept Procedure. Today, we are pleased to announce the launch of several new instruments offering greater control, precision, and ease of use during the procedure,” Tyler Binney, president and CEO of Relievant told the press. “These next-generation Intracept Access Instruments are purpose built to enhance BVN access and procedural efficiency while consistently delivering positive outcomes.”
The company said over 10,00 patients have been treated using the minimally invasive Intracept procedure, which is the only FDA-cleared treatment for chronic, vertebrogenic low back pain. The same-day, outpatient procedure enlists targeted radiofrequency (RF) energy to stop the BVN from sending pain signals to the brain. The procedure takes about an hour to perform.
The next-gen instruments feature bevel and diamond introducers for consistent access, with a depth marker for best positioning. A curved cannula assembly with J-stylet allows steerability to form a predictable path to the BVN. The Intracept RF probe (which dispenses targeted RF energy) how has a flexible shaft for more C-arm operating clearance.
Last month, the Intracept procedure gained national coverage from Cigna Healthcare for all 50 states, Washington D.C., and Puerto Rico. Relievant also publicized results from two clinical trials validating Intracept for vertebrogenic pain last month.
According to the company, the new instruments can provide more predictable and precise basivertebral nerve (BVN) targeting during the company’s Intracept procedure.
“We are committed to continued innovation in support of our physicians as we expand patient treatment with the Intracept Procedure. Today, we are pleased to announce the launch of several new instruments offering greater control, precision, and ease of use during the procedure,” Tyler Binney, president and CEO of Relievant told the press. “These next-generation Intracept Access Instruments are purpose built to enhance BVN access and procedural efficiency while consistently delivering positive outcomes.”
The company said over 10,00 patients have been treated using the minimally invasive Intracept procedure, which is the only FDA-cleared treatment for chronic, vertebrogenic low back pain. The same-day, outpatient procedure enlists targeted radiofrequency (RF) energy to stop the BVN from sending pain signals to the brain. The procedure takes about an hour to perform.
The next-gen instruments feature bevel and diamond introducers for consistent access, with a depth marker for best positioning. A curved cannula assembly with J-stylet allows steerability to form a predictable path to the BVN. The Intracept RF probe (which dispenses targeted RF energy) how has a flexible shaft for more C-arm operating clearance.
Last month, the Intracept procedure gained national coverage from Cigna Healthcare for all 50 states, Washington D.C., and Puerto Rico. Relievant also publicized results from two clinical trials validating Intracept for vertebrogenic pain last month.